CIK 0000812796 · Non-accelerated filer<br>Smaller reporting company
SOLIGENIX, INC.
Sign in to watch- Ticker
- SNGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 411505029
- Phone
- 609-538-8200
- Business address
- 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ, 08540
- Former names
- SOLIGENIX, INC., DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-12 | Parks Diane L. Director | Grant or award · Stock Option (Right to Buy) | +8,646 | 8,646 | ||
| 2024-12-12 | Donini Oreola CSO | Grant or award · Option (Right to Buy) | +20,000 | 20,000 | ||
| 2024-12-12 | Guarino Jonathan L. CHIEF FINANCIAL OFFICER | Grant or award · Option (Right to Buy) | +20,000 | 20,000 | ||
| 2024-12-12 | Straube Richard SENIOR VICE PRESIDENT AND CMO | Grant or award · Option (Right to Buy) | +12,000 | 12,000 | ||
| 2024-12-12 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Grant or award · Option (Right to Buy) | +45,000 | 45,000 | ||
| 2024-12-12 | LAPOINTE ANTHONY GREGG Director | Grant or award · Stock Option (Right to Buy) | +8,646 | 8,646 | ||
| 2024-12-12 | ZELDIS JEROME B Director | Grant or award · Stock Option (Right to Buy) | +8,646 | 8,646 | ||
| 2024-12-12 | RUBIN ROBERT J. Director | Grant or award · Stock Option (Right to Buy) | +8,646 | 8,646 | ||
| 2023-12-15 | ZELDIS JEROME B Director | Grant or award · Stock Option (Right to Buy) | +38,136 | 38,136 | ||
| 2023-12-15 | Parks Diane L. Director | Grant or award · Stock Option (Right to Buy) | +38,136 | 38,136 | ||
| 2023-12-15 | RUBIN ROBERT J. Director | Grant or award · Stock Option (Right to Buy) | +38,136 | 38,136 | ||
| 2023-12-15 | LAPOINTE ANTHONY GREGG Director | Grant or award · Stock Option (Right to Buy) | +38,136 | 38,136 | ||
| 2023-12-08 | Donini Oreola CSO | Grant or award · Option (Right to Buy) | +90,000 | 90,000 | ||
| 2023-12-08 | Straube Richard SENIOR VICE PRESIDENT AND CMO | Grant or award · Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-12-08 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Grant or award · Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-12-08 | Guarino Jonathan L. CHIEF FINANCIAL OFFICER | Grant or award · Option (Right to Buy) | +90,000 | 90,000 | ||
| 2023-05-03 | Cote Timothy R. Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-12-08 | Straube Richard SENIOR VICE PRESIDENT AND CMO | Grant or award · Option (Right to Buy) | +80,000 | 80,000 | ||
| 2022-12-08 | Donini Oreola CSO | Grant or award · Option (Right to Buy) | +80,000 | 80,000 | ||
| 2022-12-08 | Guarino Jonathan L. CHIEF FINANCIAL OFFICER | Grant or award · Option (Right to Buy) | +80,000 | 80,000 |
Page 4 of 8 · 141 trades